Global cervical cancer vaccine market research report

1
Global Cervical Cancer Vaccine Market Opportunitie
s, 2020
P h a r m a H e a l t h c a r e C o n
s u l t a n t s
2
R e s e a r c h M e t h o d o l o g y Baseline
Methodology For the study, Pharmaion has
gathered information through primary research
with respondents in cervical cancer vaccine
manufacturers across the globe. We also gathered
insights through an exhaustive search of credible
paid databases and our internal database. Since
an HPV(Human Papilloma Vaccine) is used by both
males and female, the report has captured only
female population using the vaccine for
prevention against cervical cancer. Our team of
analysts has then prudently evaluated all the
collected information and presented the same in
chronological order to depict a meaningful and
clear picture of cervical cancer vaccine market
in all the regions across the world.
While compiling the data, we have also
validated all the collected information from
multiple sources and data warehouses, in order
to present accurate and precise information of
the concerned industry. The information has then
been verified with primary research surveys with
competitors to arrive at logical figures.
Companies Interviewed
Merck Co Inc., Sanofi Pasteur MSD, GlaxoSmithKline
Sources World Health Organisation, GLOBOLCAN,
Company Annual Reports and Investors
Presentations
2
Pharmaion
3
T a b l e
o f C o n t e n t s
S No. Contents Contents Contents
1. Product Overview Product Overview Product Overview
2. Research Methodology Research Methodology Research Methodology
3. Analyst View Analyst View Analyst View
4. Global Cervical Cancer Patient Epidemiology Global Cervical Cancer Patient Epidemiology Global Cervical Cancer Patient Epidemiology
5. Global Cervical Cancer Vaccine Market Outlook Global Cervical Cancer Vaccine Market Outlook Global Cervical Cancer Vaccine Market Outlook
5.1. Market Size Forecast Market Size Forecast
5.1.1. By Value
5.2. Market Share Forecast Market Share Forecast
5.2.1. By Region
5.2.2. By Company
6. United States Cervical Cancer Vaccine Market Outlook United States Cervical Cancer Vaccine Market Outlook United States Cervical Cancer Vaccine Market Outlook
6.1. Market Size Forecast Market Size Forecast
6.1.1. By Value
6.1.2. By Volume
6.2. Market Share Forecast Market Share Forecast
6.2.1. By Company
6.3. US Cervical Cancer Patient Epidemiology US Cervical Cancer Patient Epidemiology
7. Europe Cervical Cancer Vaccine Market Outlook Europe Cervical Cancer Vaccine Market Outlook Europe Cervical Cancer Vaccine Market Outlook
7.1. Market Size Forecast Market Size Forecast
7.1.1. By Value
7.1.2. By Volume
7.2. Market Share Forecast Market Share Forecast
7.2.1. By Company
2
Pharmaion
4
T a b l e
o f C o n t e n t s
S No. Contents Contents Contents
7.3. Europe Cervical Cancer Patient Epidemiology Europe Cervical Cancer Patient Epidemiology
8. ROW Cervical Cancer Vaccine Market Outlook ROW Cervical Cancer Vaccine Market Outlook ROW Cervical Cancer Vaccine Market Outlook
8.1. Market Size Forecast Market Size Forecast
8.1.1. By Value
8.2. Market Share Forecast Market Share Forecast
8.2.1. By Company
9. Market Dynamics Market Dynamics Market Dynamics
9.1. Drivers Drivers
9.2. Challenges Challenges
10. Market Trends Developments Market Trends Developments Market Trends Developments
10.1. New Product Development New Product Development
10.2. Patient Assistance Program Patient Assistance Program
10.3. Reduced HPV Vaccine Dosage Reduced HPV Vaccine Dosage
10.4. Expanding Involvement of Pharmacists Expanding Involvement of Pharmacists
11. Competitive Landscape Competitive Landscape Competitive Landscape
11.1. Merck Co., Inc. (NYSE MRK) Merck Co., Inc. (NYSE MRK)
11.1.1. Company Overview
11.1.2. Regulatory Footprint Gardasil
11.1.3. Clinical Highlights Gardasil
11.2. GlaxoSmithKline plc (LSEGSK.L) GlaxoSmithKline plc (LSEGSK.L)
11.2.1. Company Overview
11.2.2. Regulatory Footprint Cervarix
11.2.3. Clinical Highlights Cervarix
11.3. Xiamen Innovax Biotech Co., Ltd. Xiamen Innovax Biotech Co., Ltd.
3
Pharmaion
5
T a b l e
o f C o n t e n t s
S No. Contents
12. Strategic Recommendations
13. About Us Disclaimer
4
Pharmaion
6
I n d u s t r y B r i e f Global Cervical
Cancer Vaccine Market to Cross US 1.6 billion by
2020 Growing prevalence of cervical cancer
coupled with favorable government initiatives to
drive global cervical cancer vaccine market
through 2020 According to recently published
Pharmaion report, Global Cervical Cancer Vaccine
Market Opportunities, 2020, global cervical
cancer vaccine market is anticipated to cross US
1.6 billion by 2020. Growth in the market is
anticipated on account of rising prevalence of
cervical cancer, various promising late- stage
pipeline candidates and vendors'
patient-assistance programs. Moreover,
governments in various countries are also
organizing different programs and initiatives to
increase awareness regarding cervical cancer and
associated vaccines available in the market.
Furthermore, reduction in the number of
recommended number of doses of HPV immunisation
from three to two is also expected to have a
positive impact on the global cervical cancer
vaccine market during 2015 - 2020. Cervical
cancer vaccines are biological preparations that
stimulate or strengthen a person's immune system
against cancer. Majorly, two cervical cancer
vaccines, namely, Gardasil (Merck Co., Inc.)
and Cervarix (GlaxoSmithKline plc), are
available across the globe. Gardasil and Cervarix
provide protection against four and two types of
HPV strains, respectively. As of 2014, Merck
Co., Inc. and GlaxoSmithKline plc were the only
two HPV vaccine producers in the global cervical
cancer market. However, Xiamen Innovax Biotech
Co., Ltd. plans to enter the global cervical
cancer market with the launch of its bivalent HPV
vaccine Cecolin. Region-wise, the United States
dominated the global cervical cancer market and
is anticipated to continue its dominance through
2020 on account of the launch of its nine-valent
HPV vaccine, Gardasil 9, in 2014, which protects
against the infection of all nine types of HPV.
Moreover, growing prevalence of cervical cancer,
high per capital income levels and favorable
reimbursement policies are expected to result in
continuance of US as the largest global cervical
cancer vaccine market through 2020.
Various strategic alliances are being signed
between public and private entities for
increasing the penetration of cervical cancer
vaccine. For instance, GAVI Alliance aims to
immunize about 2 million females in developing
regions in 2015 using the HPV vaccines Cervarix
and Gardasil, which are being supplied at a low
cost by GlaxoSmithKline and Merck. Moreover, in
the US, National Vaccine Program Office (NVPO)
inked a partnership contract with the American
Pharmacists Association (APhA) in 2015 in order
to utilize alternative vaccination sites, such
as pharmacies, to increase the vaccination access
and coverage rates in the country. said Mr.
Karan Chechi, Research Director with Pharmaion, a
research based global pharmaceutical and
healthcare consulting firm.
6
Pharmaion
7
P r o d u c t O v e r v i e w
Cervical Cancer occurs when abnormal cells on the
surface of cervix, which is the lower part of
the uterus of a womans body, begin to divide
rapidly.
The cancer is mainly caused by the infection of
Human Papilloma Virus (HPV), which is
transmitted through sexual contact with an
HPV-infected person.

• Typically, there are two strains of Human
  Papilloma Virus (HPV) which causes cervical
  cancer
• HPV X
• HPV X
• Cervical Cancer Vaccine The vaccines which are
  used to prevent the infection caused by
  different HPV types, associated with the
  development of cervical cancer, are termed as
  cervical cancer vaccine.

7
Pharmaion
8
P r o d u c t O v e r v i e w
Process of Development of Cervical Cancer after
an HPV Infection
HPV Virus Persistence Progression
Cervix Infected with high-risk HPV
Precancerous Lesion
Normal Cervix
Cancer
Invasion
Regression
Clearance
Persistence of a HPV virus infection for more
than a year increases the risk of cervical
cancer. Due to the HPV infection, cervix
witnesses abnormal cellular changes known as
Cervical Intraepithelial Neoplasia
(CIN). Majority of CIN rapidly regresses,
however, they posses the potential to develop
into invasive cervical cancer.
It takes approximately X or X years for the
development of cervical cancer from the time of
high-risk HPV infection.
8
Pharmaion
9
S a m p l e
D a t a - S n a p s h o t
Australia HPV 3 Dose Vaccine Coverage for
Females of Age 15 years, By State, By Number,
2014
United States Gardasil and Cervarix Vaccine for
Children, Average Selling Price (ASP),
2010-2014, (USD/Dose) 11
NSW- XXXX VIC- XXXX WA- XXXX SA- XXXX TAS-
XXXX ACT- XXXX NT- XXXX
9
7
5 5
4
7
3
3
2
1
6
5
2010 2011
2012 2013 2014 Gardasil
4
3
United States Percentage of 13 to 17 Year-old
Girls Completing HPV Vaccine 3 Dose, 2012
2
X
1
X
X X X X
X
X X X X
X
NSW
VIC
WA
SA
TAS
ACT
NT
XX
X
X
X
X
X
XX

X

United States Cervical Cancer Vaccine Market
Share, By Company, By Value, 2010-2020F
X X
X
X
X
X X X
gt X
X
X
X

X X
50.00 50.10 50.20 50.30 50.40 50.50 50.60
50.70 50.80 50.90 51.00
X
X
X
Alaska
X
X
4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07
4.08 4.09 4.10
Hawaii
lt X
2010 2011 2012 2013 2014 2015E 2016F
2017F 2018F 2019F 2020F GlaxoSmithKline
Global Cervical Cancer Vaccine Market Share, By
Region, By Value, 2010-2020F
36.00 36.01 36.02 36.03 36.04
36.05 36.06 36.07 36.08 36.0936.10
Global Cervical Cancer Vaccine Market Size,
By Value, 2010-2020F (USD Million)
31.00 31.01 31.02 31.03 31.04 31.05 31.06 31.07 31.08 31.09 31.10
28.00 28.01 28.02 28.03 28.04 28.05 28.06 28.07 28.08 28.09 28.10
12
11
10
9
8
7
5
4
3
2
2010
2011
2012
2013
2014
2015E
2016F
2017F
2018F 2019F
2020F
1
9
2010 2011 2012 2013 2014
2015E 2016F 2017F 2018F 2019F 2020F
Rest of the World
European Union
United States
Pharmaion
10
Report Name Global Cervical Cancer Vaccine
Market Opportunities, 2020
R e p o r t O r d e r i n g
Report Price
License Type Price
Single User License 4000
Single User License Print 4500
Enterprise License 8000
To View Sample OR Purchase Report
10
Pharmaion

11
A b o u t U s D i s c l a i m e r About Us
Pharmaion is a research based management
consulting firm focused exclusively on Healthcare
Pharmaceutical industry. Pharmaions core
values are value, integrity and insight. Led by a
team of dynamic industry experts, Pharmaion
provides its customers with high value market
research and advisory services that helps them
identify new market opportunities, growth engines
and innovative ways to capture the market share.
As a result, Pharmaions clients lead rather than
follow market trends. Not bound by legacy,
Pharmaions cutting-edge research model leverages
its decades of research knowledge and an
increased use of technology as engines of
innovation to deliver unique research value.
Provided as an alternative to traditional market
research, Pharmaions reports do not just
deliver data and knowledge rather highlights the
insights in a more usable and interactive format
for its clients. Pharmaion is committed to
assisting customers worldwide with their unique
market research needs by providing them with
comprehensive, value-added solutions and
professional market intelligence services.
Pharmaion employs the industrys best-trained
industry Analysts and Consultants, which advises
and assists customers in meeting their full
service market research and consulting
requirements. Related Reports India Stem Cell
Market Forecast Opportunities, 2020 Global
Tissue Engineered Medical Devices Market Forecast
Opportunities, 2020 Global Cervical Cancer
Vaccine Market Forecast Opportunities,
2020 Disclaimer The contents of this report
are based on information generally available to
the public from sources believed to be reliable.
No representation is made that it is timely,
accurate or complete. Pharmaion Consultants has
taken due care and caution in compilation of data
as this has been obtained from various sources
including which it considers reliable and first
hand. However, Pharmaion Consultants does not
guarantee the accuracy, adequacy or completeness
of any information and it is not responsible for
any errors or omissions or for the results
obtained from the use of such information and
especially states that it has no financial
liability whatsoever to the subscribers / users
of this report. The information herein, together
with all estimates and forecasts, can change
without notice. All the figures provided in this
document are indicative of relative market size
and are strictly for clients internal
consumption. Usage of the same for purpose other
than internal will require prior approval of
Pharmaion Consultants.
NORTH AMERICA Pharmaion Consultants LLC 708 3RD
Avenue, 6th Floor, New York, NY, United State,
10017 sales_at_pharmaion.com 1 646 360
1656 www.pharmaion.com
ASIA PACIFIC Pharmaion Consultants Pvt. Ltd. A
51, Sector 57, Noida, National Capital
Region, India - 201301 sales_at_pharmaion.com 91 -
120 - 452 3900 www.pharmaion.com
105
Pharmaion